Octapharma AG

75 articles with Octapharma AG

• Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

  2/22/2021

  Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis

• Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A

  2/18/2021

  Octapharma announced that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study” https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).

• Akron Biotech Signs Exclusive Global Agreement with Octapharma to Produce Virally Inactivated Human AB Serum Derived from Octaplas® for the Cell Therapy Market

  1/20/2021

  Akron Biotechnology, LLC, announced it has signed an exclusive global agreement to manufacture virally inactivated Human AB Serum for the cell therapy market using Octaplas®, Octapharma’s pooled, solvent-detergent treated human plasma.

• Octapharma to Demonstrate Ongoing Commitment to Improving the Long-term Health of People With Haemophilia A at the 14th EAHAD Annual Congress

  1/11/2021

  Octapharma announced a satellite symposium and poster presentation at the 14th annual congress of the European Association for Haemophilia and Allied Disorders, which will be held virtually from February 3–5, 2021.

• Positive Results From ProDERM Study of octagam® 10% in Patients With Dermatomyositis Meeting the Primary Endpoint Will Be Presented at ACR Convergence 2020

  11/6/2020

  Octapharma announces that the final results from the phase III ProDERM study will be presented at the American College of Rheumatology (ACR) Convergence 2020 virtual meeting.

• 

  Octapharma Uses IVIG as Potential Treatment for COVID-19

  8/7/2020

  Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.

• New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders

  7/13/2020

  Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020. The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq ® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final re

• Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga® (NewGam) in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) presented at AAN 2020

  5/18/2020

  Octapharma has announced that results from the ProCID study were shared for the first time as a poster presentation during the virtual American Academy of Neurology 2020 annual meeting.

• Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

  4/6/2020

  Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

• CORRECTING and REPLACING Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

  4/6/2020

  Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

• Octapharma demonstrates commitment to improving haemophilia A treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

  2/6/2020

  Octapharma had a prominent role as a Sponsor of the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders Congress this week, which takes place in The Hague, The Netherlands, from February 5–7, 2020.

• Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019

  12/10/2019

  Octapharma has announced that the final results from the NuProtect study, the largest prospective study of a single factor VIII product in true PUPs with severe haemophilia A, were presented in an oral presentation at the American Society of Hematology 2019 Annual Meeting in Orlando, Florida.

• Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019

  12/2/2019

  Octapharma has announced that the final results of the NuProtect study will be presented by Dr Ri Liesner as an oral presentation at the 61st Annual Meeting of the American Society of Hematology 2019 in Orlando, Florida.

• Octapharma announces publication of data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

  10/31/2019

  Octapharma has announced the publication of new data demonstrating that the fibrinogen concentrate fibryga® is an effective alternative to cryoprecipitate for patients with severe bleeding during cardiac surgery.

• Octapharma Adopts Genedata Bioprocess to Develop Next-generation Bio-manufacturing Processes

  10/29/2019

  Leading manufacturer of therapeutic proteins implements Genedata Bioprocess to streamline development and manufacture of biopharmaceuticals

• Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis

  9/30/2019

  Octapharma announced that the European Medicines Agency has authorised an updated Summary of Product Characteristics for Nuwiq® that includes information on personalised prophylaxis in patients with haemophilia A.

• Octapharma Present New Data on the Benefits Of Nuwiq® In Patients With Haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress

  7/8/2019

  Octapharma announced that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a scientific symposium at the 27th International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia.

• Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019

  7/7/2019

  Octapharma announced that an update on the clinical development plan and pre-clinical data with SubQ-8 were presented in a scientific symposium at the 27th International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia.

• Octapharma to Present New Data on Management of People with Haemophilia A or von Willebrand Disease at ISTH 2019

  7/2/2019

  New scientific data on Octapharma’s Haematology portfolio will be presented at the upcoming 27th Congress of the International Society on Thrombosis and Haemostasis, taking place in Melbourne, Australia, from 6 to 10 July 2019.

• Octapharma Study Presented at CIS Demonstrates cutaquig® Efficacy and Safety

  5/6/2019

  Research on Subcutaneous Immunoglobulin Reports Zero Serious Bacterial Infections